Shenzhen Genvict Technologies (002869.SZ) shareholder Wang Lijuan plans to reduce holdings of no more than 776,300 shares.
Shenzhen Genvict Technologies (002869.SZ) announced that its shareholder Wang Lijuan plans to reduce her holdings of the company's shares by no more than 776,300 shares (representing 0.45% of the company's total share capital excluding the shares in the dedicated repurchase securities account, and 0.44% of the company's total share capital) through centralized bidding or block trading within 3 months after 15 trading days from the date of the announcement disclosure.
Shenzhen Genvict Technologies (002869.SZ) announced that its shareholder Wang Lijuan plans to reduce her holdings of the company's shares by no more than 776,300 shares (representing 0.45% of the company's total share capital excluding the dedicated repurchase securities account, and 0.44% of the company's total share capital) through centralized bidding or block trades within 3 months after 15 trading days from the date of the announcement's disclosure.
Related Articles
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
